Inhibrx Biosciences, Inc.
ozekibart (INBRX-109)
unresectable or metastatic conventional chondrosarcoma
Countdown
281days
FDA decision · Apr 14, 2027
What's at stake
The FDA's approval decision on ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma is due Apr 14, 2027. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.”